We are live on ! Find out more
IMCR icon

Immunocore

119 hedge funds and large institutions have $2.11B invested in Immunocore in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

659% more call options, than puts

Call options by funds: $27.2M | Put options by funds: $3.58M

200% more capital inflows, than outflows

Capital inflows: $231M | Capital outflows: $77.1M

100% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 25

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

9% more funds holding

Funds holding: 109 → 119 (+10)

8.44% more ownership

Funds ownership: 67.93% → 76.37% (+8.4%)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

Holders
119
Holders Change
+10
Holders Change %
+9.17%
% of All Funds
1.86%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
28
Increased
50
Reduced
25
Closed
16
Calls
$27.2​M
Puts
$3.58​M
Net Calls
+$23.6​M
Net Calls Change
+$4.11​M

IMCR Hedge Fund Activity: Q2 2023 in Review

119 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q2 2023, worth a combined $2.11B — up 31% from $1.61B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new IMCR positions and 16 closed out — a net gain of 12 holders — while 50 added to existing stakes and 25 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $59.4M. The largest seller was Avidity Partners Management, cutting an estimated $11.1M.

  • 119 institutional investors held Immunocore (IMCR) as of Q2 2023, up from 109 in Q1 2023.
  • Funds reported $2.11B of Immunocore stock for Q2 2023, up 31% quarter-over-quarter.
  • 28 funds opened new Immunocore positions in Q2 2023 and 16 closed out, a net change of +12 holders.
  • The largest Immunocore buyer in Q2 2023 was T. Rowe Price Associates, an estimated $59.4M added.
  • The largest Immunocore seller in Q2 2023 was Avidity Partners Management, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2023.